GSK'872 is a potent and selective inhibitor of receptor-interacting protein kinase 3 (RIPK3), a key player in the necroptosis pathway—a form of regulated cell death. Its primary application lies in research settings, where it is used to investigate the role of necroptosis in various disease models. It has been widely applied in studies related to inflammatory diseases, neurodegenerative disorders, and tissue injury. For example, in models of neuroinflammation such as multiple sclerosis or Alzheimer’s disease, GSK'872 helps dissect how necroptotic signaling contributes to neuronal damage. It is also used in research on ischemia-reperfusion injury, including stroke and myocardial infarction, where inhibition of RIPK3 has shown protective effects. Additionally, GSK'872 is employed to explore the interplay between apoptosis, necroptosis, and immune responses, particularly in viral infections and autoimmune conditions. By selectively blocking RIPK3, it allows researchers to determine whether therapeutic targeting of necroptosis can reduce inflammation and tissue damage without compromising essential cell death mechanisms. Due to its research-focused use, GSK'872 serves as a critical tool compound in validating RIPK3 as a drug target and in guiding the development of future therapeutics aimed at modulating cell death pathways.